504279916 03/20/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4326598

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MATTERN PHARMA AG	03/18/2017

RECEIVING PARTY DATA

Name:	M ET P PHARMA AG	
Street Address:	SCHYNWEG 7	
City:	EMMETTEN	
State/Country:	SWITZERLAND	
Postal Code:	6376	

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	62448556
Patent Number:	8609043
Patent Number:	8784882
Patent Number:	8574622
Patent Number:	8877230
Patent Number:	9186320
Patent Number:	8784869
Patent Number:	9238072
Patent Number:	9579280
Application Number:	14881332
Application Number:	15403627

CORRESPONDENCE DATA

Fax Number: (202)672-5399

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-672-5300 Email: carthur@foley.com

Correspondent Name: FOLEY & LARDNER LLP Address Line 1: 3000 K STREET N.W.

Address Line 4: WASHINGTON, D.C. 20007

PATENT REEL: 041645 FRAME: 0897

ATTORNEY DOCKET NUMBER: 054905-0104	
NAME OF SUBMITTER: COURTENAY C. BRINCKERHOFF	
SIGNATURE:	/Courtenay C. Brinckerhoff/
DATE SIGNED:	03/20/2017
Total Attachments: 3 source=metpassignment#page1.tif source=metpassignment#page2.tif source=metpassignment#page3.tif	

PATENT REEL: 041645 FRAME: 0898

ASSIGNMENT - WORLDWIDE

WHEREAS, MATTERN PHARMA AG of Fundationasanstalt, Heiligkreuz 6, Vaduz, Liechentenstein 9490 (hereinafter "Assignor"), is the owner of the following United States Letters Patents and applications therefore, and the inventions set forth therein, as shown by the records of the United States Patent and Trademark Office:

U.S. PATENT APPLICATION NO. or U.S. PATENT NO.	FILING or GRANT DATE	TITLE
62/448,556	1/20/2017	NASAL PHARMACEUTICAL COMPOSITIONS FOR REDUCING THE RISKS OF EXPOSURE TO AIR POLLUTANTS
8,609,043	12/17/2013	USE OF A CONTAINER OF AN INORGANIC ADDITIVE CONTAINING PLASTIC MATERIAL
8,784,882	07/22/2014	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT
8,574,622	11/05/2013	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS
8,877,230	11/04/2014	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS
9,186,320	11/17/2015	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS
8,784,869	07/22/2014	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHODS OF TREATMENT
9,238,072	01/19/2016	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT
9,579,280	02/28/2017	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT
14/881,332	10/13/2015	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS
15/403,627	01/11/2017	CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT

WHEREAS, M et P PHARMA AG, of Schynweg 7, 6376 Emmetten, Switzerland, (hereinafter referred to as "Assignee") its successors and assigns, is desirous of acquiring the full, entire, and exclusive right, title and interest in and to said Patents, applications, and inventions for the United States of America, its territories and possessions, and all countries foreign thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to Assignee the full, entire and exclusive right, title and interest in and to said Patents, applications, and inventions, as well as in and to (a) all improvements and modifications of the above-identified inventions, (b) the above-identified applications and all other applications for Letters Patent of the United States and countries foreign thereto for the above-identified inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications and Patents the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by Assignee, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by Assignor had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

The undersigned hereby grant the firm of FOLEY & LARDNER LLP the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

MATTERN PHARMA AG Assignor	
Date: 19,3,17	Ву:
	Name: Udo Mattern
	Title: CEO
Accepted by: M et P PHARMA AG Assignee	
Date: <u> </u>	Ву:
	Name: Udo Mattern

Title: CEO

RECORDED: 03/20/2017